The dNTP NIPT (Non-Invasive Prenatal Testing) Prenatal Test is a non-invasive screening test used during pregnancy to assess the risk of certain chromosomal abnormalities in the developing fetus. This test is typically performed around the 10th week of pregnancy or later and is an alternative to traditional invasive procedures such as amniocentesis or chorionic villus sampling (CVS).
The dNTP NIPT Prenatal Test primarily screens for the following chromosomal abnormalities:
Down Syndrome (Trisomy 21): This is a genetic condition caused by an extra copy of chromosome 21. Individuals with Down syndrome may have intellectual disabilities and various physical features.
Edwards Syndrome (Trisomy 18): Edwards syndrome is characterized by the presence of an extra copy of chromosome 18. It is associated with severe developmental and medical complications, often leading to a shortened lifespan.
Patau Syndrome (Trisomy 13): Patau syndrome results from an extra copy of chromosome 13 and is associated with severe intellectual disabilities and multiple physical abnormalities.
associated with severe intellectual disabilities and multiple physical abnormalities.
Additionally, the dNTP NIPT Prenatal Test may also screen for sex chromosome abnormalities, such as Turner syndrome and Klinefelter syndrome, as well as provide information about the baby’s gender, if requested by selecting “Sex chromosome aneuploidies” in the requisition form.
The test is considered non-invasive because it involves a simple blood draw from the pregnant mother, analyzing cell-free fetal DNA (cfDNA) that is naturally present in her bloodstream. By examining this DNA, the test can estimate the likelihood of these chromosomal abnormalities in the fetus. It is important to note that while NIPT is highly accurate, it is still a screening test and not a diagnostic test. If the results suggest an increased risk, further diagnostic testing, such as amniocentesis or CVS, may be recommended to confirm the findings.
Unlike invasive procedures like amniocentesis or chorionic villus sampling (CVS), NIPT only requires a maternal blood sample, posing no risk to the fetus.
NIPT is a safe option for all pregnant women, including those at high risk for chromosomal abnormalities or those who prefer a non-invasive option.
The test can provide detailed information about the fetal genome, offering insights that can guide further diagnostic procedures if necessary.
With its high accuracy, NIPT can significantly reduce the need for follow-up invasive diagnostic tests like amniocentesis, which carry risks of miscarriage.
By providing reliable information early in pregnancy, NIPT helps healthcare providers and parents make informed decisions about the need for any further testing or interventions.
Next-generation NIPT is suitable for both low-risk and high-risk pregnancies, making it a versatile tool in prenatal care.
The detailed genetic information obtained from NIPT allows healthcare providers to create more personalized prenatal care plans, addressing specific risks identified through the test.
If abnormalities are detected, early diagnosis through NIPT enables early intervention, whether that involves additional monitoring, preparation for potential complications, or decisions regarding the pregnancy.
We’re here to help! Whether you have questions, need more information, or are ready to get started, don’t hesitate to reach out.
CLIA# 31D2245011
CAP# 9314196
PFI# 9752